Upstream Bio (UPB) Profit After Tax (2023 - 2026)
Upstream Bio (UPB) posted quarterly Profit After Tax of -$40.6 million for Q1 2026, down 48.68% year-over-year from -$79.1 million in Q1 2025, and up 4.36% quarter-over-quarter from -$42.4 million in Q4 2025.
Upstream Bio (UPB) Profit After Tax (2023 - 2026) Analysis & Trends
Upstream Bio's Profit After Tax history runs 4 years deep, the most recent figure standing at -$40.6 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 48.68% year-over-year to -$40.6 million; the TTM figure through Mar 2026 stood at -$156.7 million (down 97.99% YoY), while the FY2025 annual figure was -$143.4 million, down 128.41% from the prior year.
- Profit After Tax for Q1 2026 stood at -$40.6 million, up from -$42.4 million in the prior quarter.
- The five-year high for Profit After Tax was -$3.1 million in Q3 2023, with the low at -$42.4 million in Q4 2025.
- The 4-year median for Profit After Tax is -$21.2 million (2024), against an average of -$23.8 million.
- The sharpest annual moves came in 2024 and 2026: Profit After Tax plunged 415.54% in 2024, then sank 48.68% in 2026.
- Upstream Bio's Profit After Tax stood at -$11.8 million in 2023, then tumbled by 79.16% to -$21.2 million in 2024, then slumped by 100.2% to -$42.4 million in 2025, then rose by 4.36% to -$40.6 million in 2026.
- Business Quant data shows UPB's Profit After Tax at -$40.6 million in Q1 2026, -$42.4 million in Q4 2025, and -$33.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | -39.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.70 Mn |
| Mar 31, 2026 | -40.59 Mn |
| Dec 31, 2025 | -42.44 Mn |
| Sep 30, 2025 | -33.75 Mn |
| Jun 30, 2025 | -39.97 Mn |
| Mar 31, 2025 | -27.30 Mn |
| Dec 31, 2024 | -21.20 Mn |
| Sep 30, 2024 | -15.99 Mn |
| Jun 30, 2024 | -14.68 Mn |
| Mar 31, 2024 | -10.89 Mn |
| Dec 31, 2023 | -11.83 Mn |
| Sep 30, 2023 | -3.10 Mn |